1.

Baseline characteristics for all patients (N=240)

Clinical characteristics	n (%)
	WHO II (N=84)	WHO III (N=84)	WHO IV (N=72)	All tumor
KPS, Karnofsky performance scale; GTR, gross total resection; EGFRvIII, epidermal growth factor receptor variant III; RT, radiotherapy; CT, chemotherapy; N/A, not available; PFS, progression-free survival; 95% CI, 95% confidence interval; OS, overall survival; WHO, World Health Organization; *, PFS was not available in 5 cases and OS was not available in 4 cases.
Gender
Male	50 (59.5)	52 (61.9)	41 (56.9)	143 (59.6)
Female	34 (40.5)	32 (38.1)	31 (43.1)	97 (40.4)
Age (year)
	40±10	40±11	48±10	42±11
Range	17−63	14−72	28−71	14−72
Tumor size (cm)
	5.5±1.5	5.9±1.8	5.8±1.6	5.7±1.6
Range	2.3−9.0	2.6−10.0	2.0−10.0	2.0−10.0
KPS score
Median (range)	90 (70−100)	80 (20−100)	80 (50−90)	80 (20−100)
Resection
GTR	58 (69.0)	54 (64.3)	52 (72.2)	164 (68.3)
Non-GTR	26 (31.0)	30 (35.7)	20 (27.8)	76 (31.7)
EGFRvIII expression
Low expression	74 (88.1)	64 (76.2)	29 (40.3)	167 (69.6)
High expression	10 (11.9)	20 (23.8)	43 (59.7)	73 (30.4)
EGFRvIII nuclear translocation
<7%	58 (69.0)	64 (76.2)	23 (31.9)	145 (60.4)
≥7%	26 (31.0)	20 (23.8)	49 (68.1)	95 (39.6)
Adjuvant treatment
RT alone	11 (13.1)	5 (6.0)	2 (2.8)	18 (7.5)
CT alone	34 (40.5)	2 (2.4)	2 (2.8)	38 (15.8)
RT and CT combination	29 (34.5)	65 (77.4)	66 (91.7)	160 (66.7)
No	10 (11.9)	4 (4.8)	2 (2.8)	16 (6.7)
N/A	0 (0)	8 (9.5)	0 (0)	8 (3.3)
Follow-up
Progression	11 (13.1)	30 (35.7)	66 (91.7)	107 (44.6)
Mean PFS (95% CI) (month)*	51.4 (50.1−52.7)	38.2 (36.0−40.4)	13.6 (12.0−15.1)	35.3 (33.9−36.7)
Dead	5 (6.0)	24 (28.6)	56 (77.8)	85 (35.4)
Mean OS (95% CI) (month)*	52.6 (51.4−53.8)	43.3 (41.6−45.0)	22.2 (20.3−24.1)	40.2 (39.0−41.4)